Customized phage therapies to eradicate
harmful bacteria in chronic diseases

Our phage therapy development and target discovery technologies were developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science
Learn about our technology

BiomX’s founders, management and investors all have a long history of excellence that is propelling us to continued success and innovation
Learn about our leadership team

BiomX News

BiomX Announces Dual Listing on the Tel-Aviv Stock Exchange

- Tel Aviv Stock Exchange trading effective February 6th, 2020 - BiomX common shares will continue to trade on the NYSE under the symbol PHGE Ness Ziona, Israel – February 3rd , 2020 – BiomX Inc. (NYSE: PHGE), a clinical-stage biotechnology company...